A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
Publication
, Conference
Liu, JF; Brady, MF; Matulonis, UA; Miller, A; Kohn, EC; Swisher, EM; Tew, WP; Cloven, NG; Muller, C; Bender, D; Moore, RG; Michelin, DP ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2020
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Liu, J. F., Brady, M. F., Matulonis, U. A., Miller, A., Kohn, E. C., Swisher, E. M., … Bookman, M. A. (2020). A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Liu, Joyce F., Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, et al. “A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.
Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, et al. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.
Liu, Joyce F., et al. “A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.
Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Tew WP, Cloven NG, Muller C, Bender D, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D’Andre SD, Carney M, Secord AA, Moxley KM, Bookman MA. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY. 2020.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences